Abstract:Internal tandem duplication of the FLT3 gene (FLT3-ITD) is one of most common genetic mutations found in patients with acute myeloid leukemia (AML). Although FLT3-ITD has been widely studied and used as an important prognostic indicator of AML in the western world, its association with disease features and prognosis in Chinese AML patients to date has rarely been investigated.In this study, 177 Chinese patients with AML were enrolled including a FLT3-ITD mutation positive group ( n = 83) and a FLT3-ITD mutation negative group ( n = 94).In FLT3-ITD-positive AML patients, the number of patients whose peripheral blood leucocyte count (≥ 100 × 10 9 /L) before treatment was significantly higher than in FLT3-ITD negative patients (32.1% vs 7.6%), but comparing to FLT3-ITD mutation negative patients, 1 year and 2 year event free survival rates (EFSR) of FLT3-ITD-positive AML patients was lower ((37.0% vs 56.0%) and (14.8% vs 38.4%)), and also their 1 year and 2 year OS rates were significantly lower ( (50% vs 100%) and (18.0% vs 36.5%)). However, it was found that the rate of induced remissions in FLT3-ITD-positive AML patients was much lower than in negative patients (39.4% vs 56.0%). The median survival time of the FLT3-ITD+/NPM1- group ( n = 39) was superior to the FLT3-ITD+/NPM1+ group ( n = 27) (16.1 months vs 5.8 months). Lastly, after comparing chemotherapy regimes, we found that the allogeneic hematopoietic stem cell transplantation treatment method significantly improved the survival rate of FLT-ITD positive AML patients (not reached vs 14.5 months). Therefore, for FLT3-ITD-positive Chinese patients with AML, the relative rate of complication with leucocyte was increased; both the event free and overall survival rates were lower, these characteristics are the same as the FLT3-ITD-positive patients in western countries. The lower induced remission rate and shorter survival time suggested FLT3-ITD+/NPM1+ mutation is inferior to FLT3-ITD+/NPM1- mutation, which is not consistant with most reports. In addition, allogeneic hematopoietic stem cell transplantation was clearly an effective treatment for patients with FLT-ITD positive AML in China. Disclosures No relevant conflicts of interest to declare.

Advances in Clinical Studies of FLT3 Inhibitors in Acute Myeloid Leukemia.

Recent advances in FLT3 inhibitors for acute myeloid leukemia.

Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors

FLT3-targeted treatment for acute myeloid leukemia

FLT3-ITD As a Prognostic Factor for Chinese Patients with Acute Myeloid Leukemia

FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations

FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance.

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions

Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade

Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment

Chemical Space of FLT3 Inhibitors As Potential Anti-AML Drugs

FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions

Progress of treatment with Fms-like receptor tyrosine kinase-3 inhibitors for acute myelogenous leukemia

“Flipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors

Advances in targeted therapy for acute myeloid leukemia

FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs

Progression of the FLT3 Inhibitor in Acute Myeloid Leukemia

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Targeting FLT3 mutations in AML: review of current knowledge and evidence

Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia

In silico and in vitro study of FLT3 inhibitors and their application in acute myeloid leukemia